Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin

• Published in: Diabetes, obesity & metabolism Vol. 25; no. 6; pp. 1769 - 1776
• Main Authors: Kim, Byungwook, Im, Dha Woon, Won, Heejae, Sunwoo, Jung, Han, Seung Seok, Lee, Hajeong, Kim, Dong Ki, Oh, Kook‐Hwan, Joo, Kwon Wook, Kim, Yon Su, Cho, Joo‐Youn, Lee, SeungHwan, Oh, Jaeseong, Jang, In‐Jin, Kim, Yong Chul
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2023; Wiley Subscription Services, Inc
• Subjects: Area Under Curve; Diabetes; diabetes mellitus; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; DPP‐4 inhibitor; end‐stage renal disease; haemodialysis; Hemodialysis; Humans; Hypoglycemic Agents; Kidney diseases; Kidney Failure, Chronic - therapy; Pharmacodynamics; Pharmacokinetics; Protease Inhibitors; Renal Dialysis; haemodialysis; pharmacokinetics; diabetes mellitus; end-stage renal disease; DPP-4 inhibitor; pharmacodynamics

Aim To investigate the possible effect of haemodialysis (HD) on the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of evogliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. Methods A single‐dose, open‐label, parallel‐group study of eight end‐stage renal disease (ESRD) patients and ei...